JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Amiselimod HCl (formerly also known as MT-1303) is a novel, potent and selective immunosuppressant and sphingosine 1 phosphate receptor (S1P1) modulator. Amiselimod can be potentially useful for treatment of multiple sclerosis, inflammatory diseases, autoimmune diseases, psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
References: Br J Pharmacol. 2016 Oct 7.; Lancet Neurol. 2016 Oct; 15(11):1148-59.
Related CAS : 942398-84-7 (HCl); 942399-20-4 (free base)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!